OABI vs. NRC, MXCT, ABSI, CORS, DTRT, LUNA, DSAQ, GWII, WRAC, and NOTV
Should you be buying OmniAb stock or one of its competitors? The main competitors of OmniAb include National Research (NRC), MaxCyte (MXCT), Absci (ABSI), Corsair Partnering (CORS), DTRT Health Acquisition (DTRT), Luna Innovations (LUNA), Direct Selling Acquisition (DSAQ), Good Works II Acquisition (GWII), Williams Rowland Acquisition (WRAC), and Inotiv (NOTV).
OmniAb (NASDAQ:OABI) and National Research (NASDAQ:NRC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership.
In the previous week, OmniAb had 4 more articles in the media than National Research. MarketBeat recorded 6 mentions for OmniAb and 2 mentions for National Research. OmniAb's average media sentiment score of 1.36 beat National Research's score of 0.32 indicating that OmniAb is being referred to more favorably in the media.
National Research received 93 more outperform votes than OmniAb when rated by MarketBeat users. However, 100.00% of users gave OmniAb an outperform vote while only 61.67% of users gave National Research an outperform vote.
OmniAb has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500. Comparatively, National Research has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.
National Research has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.
OmniAb presently has a consensus price target of $9.00, indicating a potential upside of 107.37%. Given OmniAb's higher probable upside, equities analysts plainly believe OmniAb is more favorable than National Research.
National Research has a net margin of 20.60% compared to OmniAb's net margin of -301.62%. National Research's return on equity of 54.83% beat OmniAb's return on equity.
72.1% of OmniAb shares are held by institutional investors. Comparatively, 47.3% of National Research shares are held by institutional investors. 8.6% of OmniAb shares are held by insiders. Comparatively, 2.0% of National Research shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
National Research beats OmniAb on 9 of the 17 factors compared between the two stocks.
Get OmniAb News Delivered to You Automatically
Sign up to receive the latest news and ratings for OABI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OABI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
